{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T01:04:38Z","timestamp":1776387878454,"version":"3.51.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Voclosporin is a novel calcineurin inhibitor approved for the treatment of adult active lupus. Based on the US Food and Drug Administration Adverse Event Reporting System FDA Adverse Event Reporting System database, this study conducted a comprehensive evaluation of the safety characteristics of voclosporin in clinical use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We selected data from the FAERS database from the 2021Q1 to 2024Q2. Disproportionality analysis was employed to detect positive signals at the System Organ Class (SOC) and Preferred Term (PT) levels. Our analysis encompassed the time to onset, and subgroup analyses stratified by gender and age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There are 3,407,094 reports collected from the FAERS database, of which 4,013 reports listed voclosporin as the \u201cprimary suspected\u201d drug. Eight positive SOC signals and 138 positive PT signals were identified, including some unexpected signals that were not listed on the drug label such as menstrual disorder (n = 7, ROR = 5.82) and acute pulmonary oedema (n = 3, ROR = 4.16). Gender differences and age differences existed in PT signals related to voclosporin. Nearly one-third of the adverse events occurred within the first month after voclosporin initiation, with a median onset time of 99\u00a0days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study clarified the characteristics of voclosporin-related adverse drug reactions, providing strong support for clinical monitoring and risk identification of voclosporin.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1506760","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T14:30:11Z","timestamp":1747665011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Post-marketing safety surveillance of voclosporin: an observational, pharmacovigilance study leveraging faers database study on the safety of voclosporin"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leping","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/opth.s2452","article-title":"A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin","volume":"2","author":"Anglade","year":"2008","journal-title":"Clin. Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/acr.25007","article-title":"Update on the efficacy and safety profile of voclosporin: an integrated analysis of clinical trials in lupus nephritis","volume":"75","author":"Arriens","year":"2023","journal-title":"Arthritis Care Res. Hob."},{"key":"B4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1111\/j.1600-6143.2011.03763.x","article-title":"The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation","volume":"11","author":"Busque","year":"2011","journal-title":"Am. J. Transpl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/0310057X19891737","article-title":"Review of anaesthetic management for cataract surgery in transplant recipients","volume":"48","author":"Chua","year":"2020","journal-title":"Anaesth. Intensive Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/rheumatology\/ker101","article-title":"Assessment of a lupus nephritis cohort over a 30-year period","volume":"50","author":"Croca","year":"2011","journal-title":"Rheumatol. Oxf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1016\/j.transproceed.2010.07.107","article-title":"Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal","volume":"42","author":"Doesch","year":"2010","journal-title":"Transpl. Proc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40620-020-00956-1","article-title":"Immunosuppression-related neurological disorders in kidney transplantation","volume":"34","author":"Faravelli","year":"2021","journal-title":"J. Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/art.37795","article-title":"Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004","volume":"65","author":"Feldman","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/art.42375","article-title":"Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades using the lupus midwest network","volume":"75","author":"Hocao\u01e7lu","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.33549\/physiolres.933332","article-title":"Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension","volume":"66","author":"Ho\u0161kov\u00e1","year":"2017","journal-title":"Physiol. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12885-022-10497-4","article-title":"Cancer incidence in immunocompromised patients: a single-center cohort study","volume":"23","author":"Ilham","year":"2023","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatol. Oxf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.3390\/cells12202440","article-title":"Voclosporin: unique chemistry, pharmacology and toxicity profile, and possible options for implementation into the management of lupus nephritis","volume":"12","author":"Kale","year":"2023","journal-title":"Cells"},{"key":"B16","doi-asserted-by":"publisher","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann. Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"bqaa162","DOI":"10.1210\/endocr\/bqaa162","article-title":"Differential effects of voclosporin and tacrolimus on insulin secretion from human islets","volume":"161","author":"Kolic","year":"2020","journal-title":"Endocrinology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1107\/S0907444910051905","article-title":"Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin)","volume":"67","author":"Kuglstatter","year":"2011","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.3390\/curroncol30060430","article-title":"Systematic review of calcineurin inhibitors and incidence of skin malignancies after kidney transplantation in adult patients: a study of 309,551 cases","volume":"30","author":"Kulbat","year":"2023","journal-title":"Curr. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/ASN.2013010026","article-title":"The pathogenesis of lupus nephritis","volume":"24","author":"Lech","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/bcp.12309","article-title":"Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin","volume":"77","author":"Ling","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B22","volume-title":"Voclosporin [prescribing information]","year":"2021"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1136\/annrheumdis-2017-212732","article-title":"Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis","volume":"77","author":"Moroni","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/164_2021_554","article-title":"Malignancy: an adverse effect of immunosuppression","volume":"272","author":"Munagala","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.3390\/ijms22073766","article-title":"Advances in lupus nephritis pathogenesis: from bench to bedside","volume":"22","author":"Obri\u015fc\u0103","year":"","journal-title":"Int. J. Mol. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1007\/s10067-021-05646-2","article-title":"Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement","volume":"40","author":"Obri\u015fc\u0103","year":"","journal-title":"Clin. Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1016\/j.transproceed.2015.08.043","article-title":"Incidence and long-term prognosis of cancer after kidney transplantation","volume":"47","author":"Pend\u00f3n-Ruiz de Mier","year":"2015","journal-title":"Transpl. Proc."},{"key":"B28","first-page":"107","article-title":"Immune disorders and susceptibility to neoplasms","volume":"4","author":"Prakash","year":"2002","journal-title":"Ochsner J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/ijms22031263","article-title":"Calcineurin and systemic lupus erythematosus: the rationale for using calcineurin inhibitors in the treatment of lupus nephritis","volume":"22","author":"Rafael-Vidal","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1681\/ASN.V42168","article-title":"Effects of cyclosporine and its metabolites in the isolated perfused rat kidney","volume":"4","author":"Roby","year":"1993","journal-title":"J. Am. Soc. Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"B33","first-page":"4S30","article-title":"Sex hormones and headache","volume":"156","author":"Silberstein","year":"2000","journal-title":"Rev. Neurol. Paris."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/s1053-2498(03)00033-0","article-title":"In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates","volume":"22","author":"Stalder","year":"2003","journal-title":"J. Heart Lung Transpl."},{"key":"B35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12873-024-01011-z","article-title":"The impact of hyperkalemia on ICU admission and mortality: a retrospective study of Chinese emergency department data","volume":"24","author":"Sun","year":"2024","journal-title":"BMC Emerg. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"905","DOI":"10.12688\/f1000research.22438.1","article-title":"A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies","volume":"9","author":"Yung","year":"2020","journal-title":"F1000Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.3892\/etm.2018.6686","article-title":"Annexin A2 and FTH1 are potential biomarkers for lupus nephritis","volume":"16","author":"Zhou","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"7578","DOI":"10.1038\/s41598-020-64587-z","article-title":"Sex- and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort","volume":"10","author":"Zitt","year":"2020","journal-title":"Sci. Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000248311","article-title":"Gender-based differences in drug prescription: relation to adverse drug reactions","volume":"84","author":"Zopf","year":"2009","journal-title":"Pharmacology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1506760\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T14:30:12Z","timestamp":1747665012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1506760\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":40,"alternative-id":["10.3389\/fphar.2025.1506760"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1506760","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"article-number":"1506760"}}